Free Trial

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Monte Rosa Therapeutics logo
$7.74 +0.11 (+1.44%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$7.64 -0.11 (-1.36%)
As of 10/3/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Advanced

Key Stats

Today's Range
$7.59
$7.86
50-Day Range
$4.19
$7.74
52-Week Range
$3.50
$12.40
Volume
586,137 shs
Average Volume
2.52 million shs
Market Capitalization
$478.01 million
P/E Ratio
21.50
Dividend Yield
N/A
Price Target
$15.33
Consensus Rating
Hold

Company Overview

Monte Rosa Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

GLUE MarketRank™: 

Monte Rosa Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 448th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monte Rosa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Monte Rosa Therapeutics has a consensus price target of $15.33, representing about 98.1% upside from its current price of $7.74.

  • Amount of Analyst Coverage

    Monte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Monte Rosa Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monte Rosa Therapeutics is 21.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 222.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monte Rosa Therapeutics is 21.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 65.27.

  • Price to Book Value per Share Ratio

    Monte Rosa Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Monte Rosa Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.84% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

  • Dividend Yield

    Monte Rosa Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monte Rosa Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.84% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

  • News Sentiment

    Monte Rosa Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for GLUE on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.

  • Percentage Held by Institutions

    79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Monte Rosa Therapeutics' insider trading history.
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GLUE Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.tc pixel
Monte Rosa stock rises after pact with Novartis
See More Headlines

GLUE Stock Analysis - Frequently Asked Questions

Monte Rosa Therapeutics' stock was trading at $6.94 at the beginning of 2025. Since then, GLUE stock has increased by 11.5% and is now trading at $7.74.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its earnings results on Thursday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.16. The firm earned $23.19 million during the quarter, compared to analyst estimates of $7.23 million. Monte Rosa Therapeutics had a trailing twelve-month return on equity of 9.95% and a net margin of 13.58%.

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/07/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLUE
CIK
1826457
Fax
N/A
Employees
90
Year Founded
2018

Price Target and Rating

High Price Target
$19.00
Low Price Target
$10.00
Potential Upside/Downside
+98.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.36
Trailing P/E Ratio
21.50
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$72.70 million
Net Margins
13.58%
Pretax Margin
15.97%
Return on Equity
9.95%
Return on Assets
6.42%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.16
Quick Ratio
7.16

Sales & Book Value

Annual Sales
$177.99 million
Price / Sales
2.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.63 per share
Price / Book
2.13

Miscellaneous

Outstanding Shares
61,759,000
Free Float
57,745,000
Market Cap
$478.01 million
Optionable
Optionable
Beta
1.54

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:GLUE) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners